This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal CardiovascularImaging. In Press European Heart Journal CV Imag 2024.This
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: CardiovascularImaging on March 13, 2024.
The Category I CPT code is an addition to the Category III CPT codes (CPT 0623T, 0624T, 0625T, 0626T) used for reporting Cleerly’s advanced coronaryatherosclerosis analysis. Derivation, Validation and Prognostic Assessment of an AI-Based Algorithm for Determination of Coronary Ischemia: The CREDENCE and PACIFIC Trial.
Presence of atherosclerosis with LDL-C and HBA1c in the ‘normal range’ What the above graph shows is that for those with an LDL-C of 3.4 mmol/l (130 mg/dl) or below, between 20-50% will already have coronaryarterydisease. For many of our traditional risk factors, normal does not mean optimal 4. JAMA Cardiol.
Circulation: CardiovascularImaging, Volume 17, Issue 2 , Page e016057, February 1, 2024. BACKGROUND:Sex-specific differences in coronary phenotypes in response to stress have not been elucidated.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content